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The global burden of cancer continues to
increase. There were an estimated 10.1 million
new cases, 6.2 million deaths, and 22.4 million
persons living with cancer in the year 2000
(Kleihues and Stewart 2003). This represents
an increase of 19% in incidence and 18% in
mortality since 1990. Given current trends in
smoking prevalence and other factors, the
annual number of new cases is estimated to
reach 15 million by 2020. It is possible to
prevent at least one-third of these new cases
through better use of existing knowledge.
Understanding how cancer develops cre-
ates opportunities for cancer prevention or
early detection. An important part of this
effort is to identify the agents and exposures
that cause cancer. Several national and inter-
national health agencies have established car-
cinogen identiﬁcation programs that provide
a scientiﬁc basis for governmental and private
efforts to control cancer by reducing exposure
to known and suspected human carcinogens.
The IARC Monographs on the Evaluation
of Carcinogenic Risks to Humans are published
by the International Agency for Research
on Cancer (IARC) of the World Health
Organization (WHO). Each IARC Monograph
represents the consensus of an international
working group of expert scientists. The IARC
Monographs include a critical review of
the pertinent peer-reviewed scientific litera-
ture as the basis for an evaluation of the
weight of the evidence that an agent may be
carcinogenic to humans. Published continu-
ously since 1972, the scope of the IARC
Monographs has expanded beyond chemicals
to include complex mixtures, occupational
exposures, lifestyle factors, physical and bio-
logic agents, and other potentially carcino-
genic exposures. After publication of IARC
Monograph volume 87, expected in 2004 or
2005, nearly 900 agents, mixtures, and expo-
sures will have been evaluated. Among these,
91 have been characterized as carcinogenic to
humans, 67 as probably carcinogenic to
humans, and 240 as possibly carcinogenic to
humans.
The U.S. National Toxicology Program
(NTP; Research Triangle Park, NC, USA) pub-
lishes the Report on Carcinogens, which identiﬁes
and discusses substances that may pose a car-
cinogenic hazard to human health and to which
a signiﬁcant number of persons residing in the
United States are exposed. Mandated in 1978
by an act of the U.S. Congress, the Report on
Carcinogens lists agents as either “known to be a
human carcinogen” or “reasonably anticipated
to be a human carcinogen.” One nongovern-
mental and two federal scientiﬁc committees
review the nominations for listing in or delisting
from the Report on Carcinogens. The director of
the National Toxicology Program reviews the
three groups’ recommendations and all public
comments before the Secretary of Health and
Human Services reviews and approves the
Report on Carcinogens (NTP 2002).
The U.S. Environmental Protection
Agency (EPA) assesses the health hazards of
chemical contaminants present in the envi-
ronment. These assessments cover cancer and
adverse effects other than cancer. The hazard
assessments are coupled with dose–response
assessments that the U.S. EPA uses in its reg-
ulatory and information programs. The prin-
ciples that the U.S. EPA uses in its cancer
assessments are discussed in an evolving series
of guidelines (U.S. EPA 1986, 1999, 2003).
Chemical assessments are developed through
a process that includes a toxicologic review of
the pertinent scientific literature written by
U.S. EPA scientists or contractors, internal
and external peer reviews, and an internal
consensus review (U.S. EPA 2004).
The California Environmental Protection
Agency (Cal/EPA) maintains a list of “chemi-
cals known to the state to cause cancer” under
Proposition 65 (Cal/EPA 2004), a 1986 bal-
lot initiative enacted to protect citizens from
chemicals known to cause cancer, birth
defects, or other reproductive harm and to
inform citizens about exposures to such
chemicals. A chemical is listed if an indepen-
dent committee of scientists and health pro-
fessionals finds that the chemical has been
clearly shown to cause cancer, if an authorita-
tive body (currently the U.S. EPA, the U.S.
Food and Drug Administration, the National
Institute for Occupational Safety and Health,
the NTP, and IARC) has identiﬁed it as caus-
ing cancer, or if a California or U.S. govern-
ment agency requires that it be labeled or
identiﬁed as causing cancer (Cal/EPA 2004).
These programs have developed the fol-
lowing descriptors:
IARC (IARC 2004)
• Carcinogenic to humans (group 1)
•P robably carcinogenic to humans (group
2A)
• Possibly carcinogenic to humans (group 2B)
• Not classiﬁable as to its carcinogenicity to
humans (group 3)
• Probably not carcinogenic to humans
(group 4)
U.S. EPA (U.S. EPA 2003)
• Carcinogenic to humans
• Likely to be carcinogenic to humans
• Suggestive evidence of carcinogenic potential
• Inadequate information to assess carcino-
genic potential
• Not likely to be carcinogenic to humans
U.S. NTP (NTP 2002)
• Known to be a human carcinogen
• Reasonably anticipated to be a human
carcinogen
Cal/EPA (Cal/EPA 2004)
• Known to the state to cause cancer.
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data often do not allow us to identify human
carcinogens with certainty and because the
costs and beneﬁts of risk reduction affect dif-
ferent segments of the population. In an effort
to identify the scientiﬁc components of these
decisions, the U.S. National Research Council
(NRC) has distinguished “risk assessment,”
which is the use of scientiﬁc data to describe
the health effects of exposure to hazardous
agents, from “risk management,” which is the
process of weighing policy alternatives and
selecting the most appropriate action (NRC
1983). Risk management integrates the results
of a risk assessment with other technical data
and with economic, social, and political
concerns (Figure 1).
The NRC further divided risk assessment
into a series of distinct steps (NRC 1983,
1994). Hazard identification determines
whether exposure to an agent is linked to
adverse health effects. Dose–response assess-
ment characterizes the relation between the
dose of an agent and the incidence of an
adverse health effect. Exposure assessment
determines the extent of human exposure
to an agent. Risk characterization describes
the nature and magnitude of human risk,
including attendant uncertainty.
Under this paradigm, a cancer “hazard” is
an agent that is capable of causing cancer under
some circumstances, whereas a cancer “risk” is
an estimate of the nature and incidence of
cancer expected from a given exposure. Risk
depends on both the existence of a hazard and
exposure to that hazard. A cancer hazard exists
even when current exposures suggest little or no
cancer risk, because accidental or unanticipated
exposures that are difﬁcult to foresee may pose a
risk of cancer. Thus, carcinogen identiﬁcation is
an exercise in hazard identification, distinct
from the tasks of estimating human dose–
response functions, estimating current or future
human exposures, or characterizing the risk
from current or future human exposures.
Pertinent data for carcinogen identifica-
tion. The term “carcinogen” generally refers to
an agent, mixture, or exposure that increases
the age-speciﬁc incidence of cancer. Carcinogen
identification is an activity grounded in the
evaluation of the results of scientiﬁc research.
Pertinent data for carcinogen identification
include human epidemiologic studies, long-
term bioassays in experimental animals, and
other relevant data on toxicokinetics and cancer
mechanisms. Each source of data has a role in
the overall assessment. Epidemiologic studies
can provide unequivocal evidence of a carcino-
genic hazard but often are not sufﬁciently sensi-
tive to identify a carcinogenic hazard except
when the risk is high or involves an unusual
form of cancer. In addition, cancer’s latent
period implies that many years of preventable
human exposure would occur before informa-
tive epidemiologic studies are available. For
these reasons, animal studies generally provide
the best means of assessing potential risks to
humans. To answer questions about the simi-
larity of response between animals and humans,
studies of toxicokinetics and mechanisms have
been employed. Toxicokinetic studies are done
to allow cross-species comparisons of absorp-
tion, distribution, metabolism, and elimination
but often are done in detail in only one species.
Mechanistic studies aim to eventually elucidate
the chemical species and cellular processes
involved in cancer initiation and development.
Evaluating evidence of cancer in humans.
Epidemiologic studies provide unique infor-
mation about the response of humans
exposed to potential carcinogens. Among
these, cohort and case–control studies are
especially useful for determining whether
exposure to an agent is causally associated
with human cancer. Criteria for assessing the
adequacy of epidemiologic studies include
selection and characterization of exposed and
reference groups, identiﬁcation and character-
ization of confounding factors and bias, dura-
tion of follow-up in view of cancer’s latent
period, ascertainment of causes of disease and
death, and power to detect speciﬁc effects.
In using human studies to identify car-
cinogens, epidemiologists often ask whether a
causal interpretation is credible and whether
chance, bias, or confounding factors can be
excluded. On the question of causality, epi-
demiologists have found useful guidance in a
set of factors known as the Hill criteria (Hill
1965; U.S. EPA 2003):
• Consistency of the observed association. A
pattern of elevated risks observed across
several independent studies would support
or strengthen an inference of causality.
Reproducibility of findings constitutes one
of the strongest arguments for causality.
• Strength of the observed association. The
ﬁnding of large, precise risks increases conﬁ-
dence that an association is not likely due to
chance, bias, or confounding factors. A
modest risk, however, does not preclude a
causal association and may reflect a lower
level of exposure, an agent of lower potency,
or a common disease (e.g., when there is a
relatively high incidence rate of a disease in
the general population, it is more difﬁcult to
reach a doubling of that incidence rate).
• Specificity of the observed association. As
originally described, this refers to a single
cause associated with a single effect (Hill
1965). Current understanding is that many
agents cause cancer at multiple sites, and
many cancers have multiple causes. Thus,
although the presence of speciﬁcity supports
causality, its absence does not exclude it.
• Temporal relationship of the observed associ-
ation. A causal interpretation is strengthened
when exposure is known to precede develop-
ment of the disease. Because cancer usually
has a latent period ≥ 20 years, it is important
to ascertain whether the study included
sufﬁcient follow-up time after exposure.
• Biologic gradient (exposure–response rela-
tionship). A clear exposure–response relation-
ship (i.e., increasing effects associated with
increasing exposure) strongly suggests cause
and effect, especially when such relationships
are observed for both level and duration of
exposure. Because an epidemiologic study
may fail to detect an exposure–response
relationship for several reasons (e.g., a small
range of observed exposure levels or expo-
sure misclassification), the absence of an
exposure–response relationship does not
exclude a causal relationship.
• Biologic plausibility. An inference of causality
is strengthened by consistency with experi-
mental data that show plausible biologic
mechanisms. A lack of mechanistic data,
however, is not a reason to reject causality.
• Coherence. Other lines of evidence—for
example, experimental animal studies,
toxicokinetic studies, short-term tests, and
mechanistic studies—may strengthen an
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Figure 1. The risk assessment paradigm.
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characterizationinference of causality. The absence of other
lines of evidence, however, is not a reason to
reject causality.
• Experimental evidence (from human popu-
lations). Experimental evidence is seldom
available from human populations and
exists only when conditions of human expo-
sure are altered to create a “natural experi-
ment” at different levels of exposure, or for
medical treatments tested in randomized
controlled trials with a sufﬁcient follow-up
period. Strong evidence for causality can be
provided when a change in exposure brings
about a change in disease frequency, for
example, the decrease in lung cancer risk
that follows cessation of smoking.
• Analogy. Evidence for causality can be
strengthened by information on an agent’s
structural analogues.
Evaluating evidence of cancer in experi-
mental animals. The most common method
for identifying potentially carcinogenic agents
is a long-term bioassay in experimental ani-
mals. Exposures can be tightly controlled and
monitored in animal bioassays, although ani-
mal responses may not correspond strictly to
human responses. Experimental carcinogene-
sis research is based on the scientiﬁc assump-
tion that agents causing cancer in animals will
have similar effects in humans (NTP 2002).
Accordingly, in the absence of adequate data
on humans, it is biologically plausible and
prudent to regard agents and mixtures for
which there is sufﬁcient evidence of carcino-
genicity in experimental animals as if they
presented a carcinogenic risk to humans
(IARC 2004).
Criteria for evaluating evidence in experi-
mental animals include the breadth of the
tumor response—for example, the induction of
tumors in multiple species or in independent
studies. When evaluating studies in experimen-
tal animals, it is important to incorporate sci-
entiﬁc experience and current understanding of
long-term carcinogenesis studies in laboratory
animals and to consider the following points:
• Adequacy of the experimental design and con-
duct (e.g., route, schedule, and duration of
exposure; species, strain, sex, and age of ani-
mal; duration of follow-up; tissues examined)
• Statistical significance of the observed
tumor response, survival-adjusted analyses,
and concerns about false positives or false
negatives
• Supporting information from proliferative
lesions (hyperplasia) at the site of neoplasia or
in other experiments (same lesion in another
sex or species)
• Progression (or lack thereof) from benign to
malignant neoplasia as well as from preneo-
plastic to neoplastic lesions; where progres-
sion is a possibility, to assume that benign
neoplasms have the potential to progress, and
to combine benign and malignant tumors
thought to represent stages of progression in
the same organ or tissue
• Occurrence of common versus uncommon
neoplasia
• Concurrent control tumor incidence, as well
as the historical control rate and variability
for a speciﬁc neoplasm (especially in the case
of uncommon neoplasia)
• Multiplicity in site-speciﬁc neoplasia
• Latency in tumor induction
• Metastases
• Presence or absence of dose–response rela-
tionships
• Structure–activity correlations
• Genetic toxicity at the site of neoplasia.
Evaluating mechanistic data. Consideration
of mechanistic data has the potential to improve
the analysis of studies in both humans and
experimental animals. Elucidation of the
mechanisms of carcinogenesis can give insight
into the biology of cancer and help identify
stages where intervention may be possible.
In evaluating human studies, mechanistic
data contribute to the discussion of biologic
plausibility when evaluating whether an
observed association is causal. If the series of
precursor events leading to tumors in humans
is understood, the observation of tumor pre-
cursors in exposed humans can provide strong
support for a carcinogenic hazard.
In evaluating experimental animal studies,
mechanistic studies can provide data to
address the question of correspondence of
response between animals and humans. This
implies sufﬁcient data to identify the mecha-
nisms contributing to the induction of the
observed animal tumors and to determine
whether analogous mechanisms may be oper-
ative in humans. If this determination is
based on tumor site concordance between
animals and humans, it is important to dis-
cuss and document the support for this
assumption, because it is not valid in general.
There has been concern recently that some
assessments have been based on untested or
incomplete mechanistic hypotheses. To illus-
trate the difﬁculty in drawing conclusions from
mechanistic data, plausible-sounding mechanis-
tic conclusions had been made simultaneously
that 1,3-butadiene both is (Melnick and Kohn
1995) and is not (Bond et al. 1995) carcino-
genic to humans. Early guidance for evaluating
mechanistic data focused on the question
of whether the available studies support a
hypothesized sequence of precursor events
[International Programme for Chemical Safety
(IPCS) 1999; U.S. EPA 1999]. Patterned after
the Hill criteria, these approaches looked at
associations between precursor events and
tumors in experimental animals.
A problem can arise, however, if insuffi-
cient consideration is given to the possibility
that more than one mechanism might be oper-
ating. This can lead to premature and false
conclusions, because associations observed
between one mechanism’s precursor events and
tumors cannot by themselves rule out the oper-
ation of other mechanisms. (This is similar to
the problem of confounding factors in epi-
demiology: There may be strong associations
between exposure and disease, but if confound-
ing factors are not examined thoroughly, the
associations may be spurious.) It is necessary to
consider that an uneven level of experimental
support for different mechanistic hypotheses
can reﬂect disproportionate resources spent on
investigating one hypothesis and does not
exclude the contribution of other mechanisms.
More recent guidance puts greater emphasis on
investigating whether multiple mechanisms
may be operating and asks that three questions
be addressed for each potential mechanism: Is
it sufficiently supported in test animals, is it
relevant to humans, and which populations
or life stages can be particularly susceptible?
(U.S. EPA 2003).
IARC’s Practice for Carcinogen
Identiﬁcation and Evaluation
The IARC Monographs are scientific evalua-
tions developed by international working
groups of expert scientists. These evaluations
provide the scientiﬁc support for public health
measures implemented by many national
and international health agencies around the
world. The process for developing the IARC
Monographs is reviewed and updated from time
to time. To promote better understanding of
the process, here we discuss the principles and
procedures currently in use.
Selection of agents and exposures for eval-
uation. Agents are selected for evaluation
based on evidence of human exposure and
some evidence or suspicion of carcinogenicity.
Agents and exposures can be reevaluated
if significant new data become available.
Periodically, IARC convenes advisory groups
to advise on priorities for future evaluation or
reevaluation (IARC 2003). These advisory
groups consist of scientists from national and
international health agencies and research
institutions, striving to include scientists from
many countries. Seeking such advice is meant
to ensure that the IARC Monographs reflect
the current state of scientiﬁc knowledge and
remain relevant to the needs of national
health agencies and the research and public
health communities.
Structure of the IARC Monographs. The
IARC Monographs are published as a series of
volumes. Each volume contains one or more
monographs, which can cover either a single
agent or a group of related agents. There is a
standard structure, which has evolved to
include sections on the following:
1. Exposure data
2. Studies of cancer in humans
3. Studies of cancer in experimental animals
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carcinogenicity and its mechanisms
5. Summary of data reported and evaluation
5.1. Exposure data
5.2. Human carcinogenicity data
5.3. Animal carcinogenicity data
5.4. Other relevant data
5.5. Evaluation
6. References.
Sections 1–4 provide a critical review of the
pertinent scientiﬁc literature. Section 5 includes
summaries of the scientiﬁc data and the evalua-
tions developed by the working group.
The preamble to the IARC Monographs
(IARC 2004) opens each volume and discusses
the principles and procedures used in develop-
ing the IARC Monographs, including the scien-
tific criteria that guide the working group’s
evaluations. The preamble promotes consis-
tency across different working groups and
provides insight into the review process and
evaluation criteria.
The critical review of the pertinent scien-
tiﬁc literature. The critical review of the perti-
nent peer-reviewed scientific literature
(sections 1–4) considers all published articles,
plus articles accepted for publication. Reports
and documents from national and interna-
tional government agencies are considered if
they are publicly available. Consensus reports
in the published literature are also considered,
subject to the same critical review as other arti-
cles, including consideration of the composi-
tion and balance of the panel that produced
the consensus. Research that is not publicly
available, including articles in preparation, is
not considered.
The critical review provides a brief, sepa-
rate, factual synopsis of each study, summariz-
ing the study’s design and results. After each
study synopsis is a separate assessment by the
working group of the study’s strengths and
limitations. These comments, which generally
appear in square brackets, provide insight into
the working group’s reasoning by revealing the
factors that might affect their interpretation or
evaluation of that study.
The evaluations. The working group
develops its evaluations through a series of
distinct steps (Figure 2). This stepwise evalua-
tion process provides insight into the working
group’s reasoning by revealing the weight
given to each line of evidence. For each agent
being evaluated, the process begins with sepa-
rate evaluations of the evidence of cancer in
humans and cancer in experimental animals,
each choosing one of four descriptors: “sufﬁ-
cient evidence,” “limited evidence,” “inade-
quate evidence,” or “evidence suggesting lack
of carcinogenicity” (for definitions of these
terms, see IARC 2004).
These two partial evaluations are combined
into a preliminary default evaluation that the
agent is “carcinogenic to humans” (group 1),
“probably carcinogenic to humans” (group 2A),
“possibly carcinogenic to humans” (group 2B),
“not classifiable as to its carcinogenicity to
humans” (group 3), or “probably not carcino-
genic to humans” (group 4). Then the mecha-
nistic and other relevant data are considered to
determine whether the default evaluation
should be modiﬁed. This determination con-
siders the strength of the mechanistic evidence
and whether the mechanism operates in
humans. The ﬁnal overall evaluation is a mat-
ter of scientiﬁc judgment, reﬂecting the weight
of the evidence derived from studies in
humans, studies in experimental animals, and
mechanistic and other relevant data. In consid-
ering all relevant scientiﬁc data, the working
group may assign the agent to a higher or
lower group than the default would indicate.
The goal is a consensus evaluation by the
working group. The evaluation will include a
synopsis that discusses the rationale for the
conclusions. If the working group is not able
to reach consensus, the overall evaluation is
determined by majority vote. In this case, the
synopsis will present the differing scientific
positions, the data that support or are incon-
sistent with each position, and the rationale
for the majority position. The evaluation can
identify research needed to test different
hypotheses, especially those that have not
received adequate research attention.
IARC Monograph meetings. Each volume,
which may contain one or more monographs,
is developed by a working group at an IARC
Monograph meeting. Each year, IARC gener-
ally convenes three separate working groups on
different topics. Meetings are announced on
the Internet (IARC 2004).
Before each meeting, IARC staff searches
and collects the pertinent scientiﬁc literature
and makes it available to the working group.
Working group members critically review the
literature and write ﬁrst drafts of sections 1–4
on exposure, cancer in humans, cancer in
experimental animals, and other relevant data,
respectively. IARC collects and formats these
ﬁrst drafts for review at the meeting.
The objectives of the meeting are review
and consensus. The ﬁrst days of the meeting
are devoted to subgroup work. Four sub-
groups, each responsible for one section, peer
review the individual members’ drafts,
develop a joint revised draft (Figure 3), and
then write the summaries that become section
5. For each agent, the subgroup on cancer in
humans proposes a partial evaluation of the
human evidence, and the subgroup on cancer
in experimental animals proposes a partial
evaluation of the animal evidence (Figure 2).
The subgroup on other relevant data charac-
terizes the mechanistic evidence using terms
such as “weak,” “moderate,” or “strong” and
discusses whether the mechanisms are likely
to be operative in humans.
In the ﬁnal days of the meeting, the sub-
groups come together in plenary session. The
entire working group peer reviews and reaches
consensus on the critical reviews in sections 1–4
and discusses and reaches consensus on the
summaries and partial evaluations proposed by
the subgroups. Then the working group as a
whole develops and reaches consensus on an
overall evaluation of each agent.
Declaration of interests by participants at
IARC Monograph meetings. IARC, part of
the WHO, follows WHO procedures with
respect to declaration of interests by partici-
pants in its meetings (WHO 2004). Each
potential participant is asked to declare, in
conﬁdence, 
any interests that could constitute a real, potential
or apparent conflict of interest, with respect to
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Figure 2. The evaluation process used in the IARC Monographs.
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Mechanism likely to be operative in humans?his/her involvement in the meeting or work,
between a) commercial entities and the participant
personally, and b) commercial entities and the
administrative unit with which the participant has
an employment relationship.
The WHO defines conflict of interest to
mean “the expert or his/her partner, or the
administrative unit with which the expert has
an employment relationship, has a ﬁnancial or
other interest that could unduly inﬂuence the
expert’s position with respect to the subject-
matter being considered.” An apparent conﬂict
of interest exists when “an interest would not
necessarily inﬂuence the expert but could result
in the expert’s objectivity being questioned by
others” (WHO 2004).
The WHO provides several examples of
ﬁnancial or other interests, including compet-
ing interests, that should be declared. The
examples include consulting work or research
support that can pose as much of a conﬂict as
employment or stock ownership. In addition,
a conflict can arise from an expectation of
future support, to the expert individually or to
the expert’s organization. On the other hand,
an interest that is no longer current becomes
immaterial after a period of time. In the case
of research support given to an expert’s organi-
zation, determining whether the conflict
warrants some limitation on participation
includes consideration of several factors, such
as the level of funding from interested parties,
whether the organization’s research or posi-
tions depend on such funding, and whether
such funding supports the expert’s own
research or position.
Before an invitation is extended, each
potential participant submits a declaration of
interests (WHO 2004). IARC assesses these
interests to determine whether there is a con-
flict that warrants some limitation on
participation. Each participant updates the
declaration of interests at the opening of the
meeting. Interests pertinent to the subject
matter of the meeting are disclosed to the
meeting participants and in the published
IARC Monograph.
Participants in IARC Monograph meet-
ings. Two principles govern the selection of
working group members: to invite the best-
qualiﬁed experts, and to avoid real or appar-
ent conflicts of interest. Consideration is
given also to demographic diversity. Members
are chosen on the basis of knowledge and
experience, which can come from research
into the specific agents to be evaluated or
from general experience in conducting or
evaluating epidemiologic or experimental
studies. Members chair the meeting and the
subgroups and are the only participants who
vote on the overall evaluations, if a vote is
needed. Working group members are invited
to serve in their individual capacities as scien-
tists and not as representatives of their gov-
ernment or any organization with which they
are afﬁliated.
A difﬁculty arises when an expert with rel-
evant knowledge and experience has a real or
apparent conflict of interest. This issue has
become more visible in recent years because
commercial interests sponsor many epidemio-
logic and experimental studies, and some
investigators develop a history of receiving
research support from interested parties. The
selection of experts with real or apparent con-
flicts of interest can erode confidence in the
integrity and impartiality of the results. This
creates a tension between two competing ideals:
evaluations developed by the best-qualified
experts versus evaluations whose integrity and
impartiality are above question.
The new category of invited specialist
allows the IARC Monographs to achieve both
ideals. An invited specialist is an expert with
critical knowledge and experience who is
recused from certain activities because of a real
or apparent conﬂict of interests. These activi-
ties include serving as meeting chair or sub-
group chair, drafting text that discusses cancer
data or contributes to the evaluations (sections
2–4 and 5.2–5.5), and participating in evalua-
tions reached by either consensus or vote.
Invited specialists are available during sub-
group and plenary discussions to contribute
the beneﬁt of their knowledge and experience.
Invited specialists also agree to serve in their
individual capacities as scientists and not as
representatives of any organization or interest.
Their conﬂicting interests are fully disclosed to
the meeting participants and in the IARC
Monograph. In this way, the meeting can
include the best-qualiﬁed experts, and the eval-
uations are developed and written by experts
with no real or apparent conﬂicts of interest.
In the interest of transparency, a limited
number of scientiﬁcally qualiﬁed observers are
welcome to attend IARC Monograph meetings.
Consideration is given to admitting observers
from different constituencies with differing
interests. The main role of observers is to serve
as sources of ﬁrst-hand information from the
meeting to the organizations that sponsor
them. Observers can play a valuable role in
ensuring that all published information and
scientific perspectives are considered. At the
meeting, the meeting chair and subgroup
chairs may grant observers the opportunity to
speak. Observers do not serve as meeting chair
or subgroup chair, draft any part of an IARC
Monograph, or participate in the evaluations.
Observers may be presumed to serve the inter-
ests of the organizations that nominate and
sponsor them, and these interests are fully dis-
closed to the meeting participants and in the
IARC Monograph. Observers are asked to agree
to ethics guidelines that include a requirement
not to lobby working group members, both
before and during the meeting. A challenge for
IARC is to increase the diversity of observers in
view of the unequal resources available to
potential observers from different sectors.
There are two other categories of partici-
pants. Representatives of national and interna-
tional health agencies (e.g., the U.S. National
Cancer Institute) often attend and provide
independent assurance and guarantee of the
integrity of the IARC Monographs. Scientists
employed by IARC comprise the IARC
Secretariat. The secretariat hosts the meeting
and drafts text or tables when requested by the
meeting chair or subgroup chair. To facilitate
consistency across different IARC Monographs,
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Figure 3. The development of drafts at IARC Monograph meetings.
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Member’s
draft Member’s
draft Member’s
draft
Member’s
draft Member’s
draft Member’s
draft
Member’s
draft Member’s
draft
Subgroup
draft
Subgroup
draft
Subgroup
draft
Working
group
draftmembers of the secretariat serve as rapporteurs
and answer questions about the preamble.
After the meeting, the secretariat reviews all
data cited in the text and tables to ensure scien-
tiﬁc accuracy and clarity and publishes the ﬁn-
ished volume. Representatives and secretariat
participate in discussions but do not vote on
the evaluations; thus, the evaluations are deter-
mined by working group members only.
Table 1 summarizes the roles of working
group members, invited specialists, observers,
representatives, and the secretariat. The pub-
lished volume identifies all participants by
name and afﬁliation and identiﬁes the meeting
chair and subgroup chairs.
Inclusion of all scientific views. When
planning a meeting, it is important to identify
the pivotal issues in advance and convene a
working group that includes all scientific
views. There are two reasons for this. First, a
balanced representation of all scientiﬁc views
promotes conﬁdence that all hypotheses and
data have been considered fully and evenly.
Second, identifying the pivotal issues can
uncover issue-related conﬂicts that would not
otherwise be apparent but may warrant some
limitation on participation. For example, the
pivotal issue of whether a particular mecha-
nism is operative in humans not only affects
the evaluation of the agent being considered
but also can set a precedent for other agents
that operate through similar mechanisms.
Identifying pivotal issues and related agents
can be difficult, but doing so will promote
conﬁdence in the working group’s objectivity.
Freedom from interference. The working
group should be free from all attempts at inter-
ference, before and during the meeting. This
includes lobbying by interested parties, receipt
of written materials from interested parties,
and meals, drinks, social events, or other favors
offered by interested parties. Attempts at inter-
ference outside the meeting are particularly
insidious, because they occur outside the
view of other participants. Such interference
destroys transparency and invites suspicion.
Working group members have assumed the
responsibility to safeguard the integrity of their
work by resisting any attempt at interference.
To aid them in this responsibility, working
group members are reminded not to discuss
the subject matter of the meeting with those
outside the meeting and are asked to report all
attempts at interference.
The Future of Carcinogen
Identiﬁcation and Evaluation
The future of carcinogen identiﬁcation will be
one of continuing evolution to reﬂect changes
in the underlying science. Future evaluations
will continue to consider mechanistic data to
aid in interpreting experimental animal results.
The task will be not only to get the right
answer based on publicly available scientific
evidence, but also to build a broad-based scien-
tiﬁc consensus around the answer. When sufﬁ-
cient data are available to identify a mechanism
of carcinogenesis, these data will also be the
key to identifying susceptible populations and
life stages, including the prenatal and early
postnatal periods. Another implication of using
mechanistic data will be carcinogen identiﬁca-
tions that are based on scientiﬁc inference in
the absence of tumor studies in humans or
experimental animals.
In addition to changes in the science, the
milieu in which carcinogens are identified is
changing rapidly. A key challenge is to main-
tain independence against the increasing
demand for access and inﬂuence by advocates
on all sides. Another is keeping current, as
more agents need evaluation because of new
scientiﬁc data or understanding.
In its practice of carcinogen identiﬁcation,
IARC is committed to the highest standards
of scientific and ethical conduct. For > 30
years the IARC Monographs have achieved a
reputation unmatched for thoroughness,
accuracy, and integrity. The principles and
procedures discussed here should ensure that
this reputation remains solid well into the
future.
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Table 1. Roles of participants at IARC Monograph meetings.
Working group Invited IARC
members specialists Observers Representatives secretariat
Before the meeting
Draft section 1 (exposure data) X X X
Draft sections 2–4 X X
During subgroup sessions
Serve as subgroup chair X
Peer review members’ drafts (sections 1–4) X X X X
Draft summary of section 1 (section 5.1) X X X
Draft summaries of sections 2–4 (sections 5.2–5.4) X X
Propose evaluations of human, animal, or mechanistic data X
During plenary session
Serve as meeting chair X
Peer review subgroup drafts and summaries X X X X
Discuss subgroup evaluations and develop the overall evaluation (section 5.5) X X X
Vote on overall evaluation, if needed X